Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm > DMARDs > Flashcards

DMARDs Flashcards

1
Q

Gold Salts MOA (7)

A
  • SUPPRESS CELLULAR IMMUNITY - Inhibit phagocytosis - Uncouple oxidative phosphorylation and inhibit cellular respiration - Stabilize lysosomal membranes and inhibit actions of lysosomal enzymes - React with proteins - Inhibit proteolytic enzymes of leukocytes - Prevent prostaglandin synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Gold Salts SE (5)

A
  • BONE MARROW DAMAGE - Dermatitis - ENTEROCOLITIS - Jaundice - Peripheral neuropathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Penicillamine MOA (2)

A
  • unknown, resembles gold and may be as effective - Chelating drug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Penicillamine SE (5)

A
  • Pruritis, rash - Alteration in taste - Thrombocytopenia, leukopenia, agranulocytosis, aplastic anemia - Proteinurina, hypoalbumin, nephrotic syndrome - Lupus like dz, pemphigus, Goodpastures, Myasthenia gravis, polymyositis, stenosing alveolitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hydroxychloroquine MOA (6)

A
  • Antihistaminic, anticholinesterase, antiprotease - Inhibits prostaglandin synthesis - Inhibits biosynth of mucopolysaccharide - Inhibits response to chemotactic stimuli and phagocytosis - Stabilizes lysosomes - Reacts with nucleic acids and tissue proteins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hydroxychloroquine SE (5)

A
  • Pruritis - Hemolysis (G6PD deficient) - Ototoxicity - Retinopathy - Peripheral neuropathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Sulfasalazine Tx

A
  • RA - IBD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Sulfasalazine SE (3)

A
  • GI disturbances - Rash - Hepatitis and dyscrasias rare - Monitoring for hepatitis and marrow suppression rec.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Agents acting on TNa (5)

A
  • Infliximab - Adalimumab - Certrolizumab pegol - Golimumab - Etanercept
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Infliximab MOA (2)

A
  • Chimeric IgG1k monoclonal antibody targeted against TNFa - Human constant and murine variable regions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Infliximab Tx (2)

A
  • Crohns - RA - Combined with methotrexate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Infliximab Admin

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Infliximab SE (2)

A
  • HA - Infusion rxn
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Infliximab CI (4)

A
  • Pregnancy - Breast feeding - Children - Infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adalimumab MOA (3)

A
  • Recombinant human IgG1 monoclonal antibody - Human derived heavy and light chain variable regions and human IgG1:k constant regions (100% HUMAN PEPTIDE SEQ) - Specific for TNFa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Adalimumab Tx

A
  • Monotherapy RA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Adalimumab Admin and t 1/2

A
  • SC - 8- 10days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Adalimumab SE (6)

A
  • Rash - Influenza-like s/s - Fatigue - HA - Pruritis - N/V
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Certrolizumab pegol MOA

A
  • Humanized antibody neutralizer of TNFa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Golimumab MOA

A
  • Human derived monoclonal antibody with human-derived variable and constant regions TNFa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Entanercept MOA (3)

A
  • Dimeric fusion protein produced by recombinant DNA technology - Consists of extracellular ligand-binding portion of the human 75 kilodalton TNF RECEPTOR linked to the Fc portion of human IgG1 - Inhibits TNF
22
Q

Entanercept Admin

A
  • SC
23
Q

Entanercept SE (3)

A
  • Injection site rxn - Infections - Increased incidence of antibody formation
24
Q

Entanercept CI (8)

A
  • Bone marrow suppression - Breast feeding - Children - DM - Infection - Sepsis - Vaccination - Varicella
25
Q

Inhibitors of B cell differentiation and T cell activation (2)

A
  • Rituximab - Abatacept
26
Q

Rituximab MOA

A
  • Genetically engineered CHIMERIC murine/human monoclonal antibody - IgG immunoglobulin containing murine light and heavy chain variable regions and human constant regions - Binds specifically to CD20 a B LYMPHOCYTE DIFFERENTIATION ANTIGEN on pre-B and mature B lymphocytes
27
Q

Rituximab Admin

A

IV

28
Q

Rituximab Tx (3)

A
  • non-Hodgkin lymphoma - refractory B cell NHL - B cell malignancies like chronic lymphocytic leukemia
29
Q

Abatacept MOA (3)

A
  • FULLY HUMAN recombinant fusion protein categorized as a costimulatory or second-signal blocker of T cell activation - Competes with CD28 (on T cell) for CD80 and CD86 (on APC) - Disturbs key mech of inflammation and progressive joint destruction in RA
30
Q

Abatacept Admin and t 1/2

A
  • IV - 13.1 days
31
Q

Inhibitors of Nucleic acid synthesis (2)

A
  • Leflunomide (pyrimidine) - Mycophenolate mofetil (purine)
32
Q

Leflunomide MOA (3)

A
  • Inhibits DHODH to stop de novo PYRIMIDINE synth - 2ndary, inhibition of cytokine and growth factor receptor associated tyrosine kinase activity - INHIBITS THE INDUCTION OF COX 2
33
Q

Leflunomide Admin and t 1/2

A
  • Oral - 16 hrs
34
Q

Leflunomide SE (4)

A
  • Diarrhea, dyspepsia, N/V - Abd pain, anorexia, wt loss, oral ulceration - Back pain - Elevated hepatic enzymes
35
Q

Leflunomide CI (4)

A
  • Pregnancy - Breast feeding - Hepatic failure - Renal failure
36
Q

Mycophenolate mofetil MOA

A
  • Prodrug for the immunosuppresive agent mycophenolic acid (MPA) - INHIBITS LYMPHOCYTIC PURINE SYNTHESIS by reversible and noncompetitively inhibiting the enzyme IMPDH
37
Q

Mycophenolate mofetil Admin

A
  • Oral - IV
38
Q

Mycophenolate mofetil SE

A
  • D/V - GI bleed
39
Q

Mycophenolate mofetil CI

A
  • Active GI bleed - Diarrhea - Pregnancy - Breast feeing - Infections
40
Q

Interleukin Receptor Antagonists (2)

A
  • Anakinra - Tocilizumab
41
Q

Anakinra MOA (1)

A
  • Recombinant, nonglycosylated form of human INTERLEUKIN-1 RECEPTOR ANTAGONIST
42
Q

Anakinra Admin and t 1/2

A
  • SC - 4 - 6hrs
43
Q

Anakinra CI (4)

A
  • Breast feeding - Children - Hypersensitivity rxn - Renal dz (eliminated renally)
44
Q

Tocilizumab MOA

A
  • Humanized interleukin-6 receptor inhibiting monoclonal antibody - Competes with IL6 for binding to receptor
45
Q

Janus Kinase Inhibitors (1)

A
  • Tofacitinib
46
Q

Tofacitinib MOA (1)

A
  • Primarily inhibits JAK1 and JAK3
47
Q

Tofacitinib Tx

A
  • Adults with mod to severe RA who have inadequate response or INTOLERANCE TO METHOTREXATE
48
Q

Tofacitinib SE

A
  • SERIOUS INFECTIONS AND MALIGNANCY
49
Q

Tofacitinib Admin and t 1/2

A
  • Oral - 3 hrs
50
Q

Penicillamine Tx (2)

A
  • RA - WILSONS Dz

Pharm (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions